Implementation of the ANA HEp-2 consensus guidelines in Brazilian clinical
            laboratories

Silva, Glaucielen G.; Gomes, Clayson Moura; Dellavance, Alessandra; Francescantônio, Paulo Luiz Carvalho; Andrade, Luís Eduardo Coelho; Cruvinel, W.M.

doi:10.5935/1676-2444.20170059

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent study carried out by Silva and collaborators (2018), with participation of 53 Brazilian clinical laboratories, it was verified that most laboratories are using five of the six terms recommended by III BCA HEp-2. The term "ANA" was present in most of these denominations [25]. Recognizing the ICAP recommendation for naming the test as indirect immunofluorescence assay on HEp-2 cells (HEp-2 IIFA), used in the most recent publications [13,23] and aiming to harmonize this report with the international current nomenclature, we will adopt in the term IIFA HEp-2 in this manuscript.…”

Section: Recommendations For Naming the Ana Testmentioning

confidence: 99%

“…Preliminary designation that may be changed according to future ICAP determinations. AC Anti-cell code (designation according to ICAP) encompasses 20, 30, 50, 120 and 200-W lamps [25]. This may represent an important factor of pattern recognition and end-titer disparity among laboratories.…”

Section: Anti-dna Topoisomerase I (Scl-70)mentioning

confidence: 99%

“…The V BCA HEp-2 maintains the recommendation of need for rigorous quality control, already disclosed at the III and IV BCA HEp-2 [3][4][5]. Such a measure is fundamental in order to restrict the occurrence of falsepositive reactions in individuals without autoimmune disease and as a measure to standardize results among different laboratories [25]. It is recommended that laboratories seek to participate in institutional quality programs and educational programs.…”

Section: Assay Quality Controlmentioning

confidence: 99%

See 2 more Smart Citations

V Brazilian consensus guidelines for detection of anti-cell autoantibodies on hep-2 cells

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background: The V Brazilian Consensus for determination of autoantibodies against cellular constituents on HEp-2 cells, held in Brasilia (DF, Brazil) on August 27, 2016, discussed the harmonization between the Brazilian Consensus on ANA (BCA) guidelines and the International Consensus on ANA Patterns (ICAP) recommendations (www.anapatterns.org). Initial guidelines were formulated by the group of Brazilian experts with the purpose of guiding and enabling Brazilian clinical laboratories to adopt recommendations and to provide a common standard for national and international consensuses.Mainbody: Twenty Brazilian researchers and experts from universities and clinical laboratories representing the various geographical regions of the country participated in the meeting. Three main topics were discussed, namely the harmonization between the BCA guidelines and latest recommendations of the ICAP initiative, the adjustment of the terminology and report on HEp-2 patterns, and a reassessment of quality assurance parameters. For the three topics, our aim was to establish specific guidelines. All recommendations were based on consensus among participants. There was concrete progress in the adjustment of the BCA guidelines to match the ICAP guidelines. To a certain extent, this derives from the fact that ICAP recommendations were largely based on the algorithm and recommendations of the IV Brazilian ANA Consensus, as consistently recognized in the ICAP publications and presentations. However, although there is great overlap between the two Consensuses, there are some point divergences. These specific items were individually and extensively discussed, and it was acknowledged that in several points ICAP improved recommendations previously issued by the Brazilian ANA Consensus and these changes were readily implemented. Regarding some specific topics, the BCA panel of experts felt that the previously issued recommendations remained relevant and possibly will require further discussion with ICAP. The term anti-cell antibodies was adopted as the recommended designation, recognizing that the assay addresses antibodies against antigens in the nucleus and in other cell compartments. However, the acronym ANA HEp-2 was maintained due to historical and regulatory reasons. It was also signalized that the latest trend in ICAP is to adopt the term Indirect Immunofluorescent Assay on HEp-2 cell substrate (HEp-2 IIFA). In addition, the quality assurance strategies previously presented were ratified and emphasized.(Continued on next page)

show abstract

Section: Recommendations For Naming the Ana Testmentioning

confidence: 99%

Section: Anti-dna Topoisomerase I (Scl-70)mentioning

confidence: 99%